Voxeralgagene Autotemcel

8月12日，PTC Therapeutics宣布，在Sangamo Therapeutics的破产拍卖中胜出，将以1.11亿美元现金首付、外加最高1亿美元里程碑款，总价最高2.11亿美元收购Sangamo用于治疗Fabry病的基因疗法ST-920（isaralgagene civaparvovec）。 真正有意思的不是2.11亿美元这个数字，而是它是怎么被“抢”出来的。两个月前，Astellas(安斯泰来)作为基准竞标方, 给ST-920开出的价格只有2500万美元首付 + 最高2500万美元里程碑款。8月10日正式拍卖开始后，PTC、Astellas和TerSera Therapeutics竞价整整两天。最终最终PTC将首付款推至1.11亿美元，是最初报价的4倍多。同一天，Sangamo还把公司的另一部分“家底”，包括衣壳递送、锌指技术和模块化整合酶MINT平台在内的核心技术资产，以5000万美元卖给了礼来。 一家曾经站在基因编辑最前沿、合作伙伴遍布全球大药企的明星Biotech，为什么最终走到了破产拆卖资产这一步？而一家已经进入破产程序的公司，为什么还有一款资产能让几家公司争抢两天，价格越拍越高？ 从基因编辑先驱到破产清算，Sangamo经历了什么 Sangamo成立于1995年，最初名为Sangamo BioSciences。在CRISPR席卷基因编辑领域之前，Sangamo押注的是另一项曾经被寄予厚望的技术：锌指核酸酶（ZFN）。2017年，Sangamo利用SB-913项目在Hunter综合征患者体内直接进行基因编辑，完成了全球最早的人体内基因编辑尝试之一，时间甚至早于CRISPR真正进入临床。 技术领先，也让Sangamo一度成为大药企争相合作的对象。巅峰时期，它的合作伙伴名单里出现过Pfizer、Sanofi、Biogen、Novartis、Kite Pharma和Takeda，合作范围横跨神经系统疾病、罕见病、血液疾病和细胞治疗。对于一家平台型Biotech而言，这样的合作阵容一度证明了外界对其技术价值的认可。但从2022年开始，市场急转直下。Sanofi首先终止了双方在镰刀型细胞病领域的合作；2023年3月，Novartis和Biogen又在同一周先后退出各自与Sangamo的神经疾病合作项目。那些原本写在合同里的巨额潜在里程碑，也随着合作终止失去了意义。 合作伙伴接连离场，很快反映到财务报表上。Sangamo的收入从2023年的1.76亿美元下降到2024年的5780万美元，跌幅约67%。今年6月23日，公司最终申请Chapter 11破产保护，并同步为核心资产寻找买家：礼来出价5000万美元收购部分核心技术平台，Astellas则计划以2500万美元首付 + 最高2500万美元里程碑款收购ST-920。但在美国破产程序中，基准竞标并不意味着交易已经尘埃落定。它更像是为待售资产确定一个最低竞价基准，其他买家仍然可以在正式拍卖中出更高的价格。真正的竞争，被留到了8月10日。 临近BLA申报，ST-920成为Sangamo最具价值的资产之一 ST-920是一款治疗Fabry病的一次性AAV基因疗法。Fabry病是一种X连锁溶酶体贮积症，由GLA基因异常导致α-半乳糖苷酶A（α-Gal A）缺乏，进而造成脂质在肾脏、心脏和神经系统等组织中累积。ST-920利用重组AAV2/6载体将正常GLA基因递送至肝脏，使肝细胞持续产生α-Gal A，试图以一次给药替代长期酶替代治疗。 真正推高ST-920价值的，是它已经接近监管终点。在注册性STAAR研究中，33名患者入组，32人完成52周随访；长期随访显示，α-Gal A酶活性提升可维持多年，生活质量及部分心脏指标也保持稳定。ST-920目前已进入BLA滚动提交阶段，PTC接手的并非一个前景未明的早期项目，而是一项已经走到监管审批门口的后期资产。这也解释了为什么Sangamo已经进入破产程序，ST-920却能在拍卖中越卖越贵：破产的是拥有资产的公司，而不是资产本身。 现有商业体系，让ST-920在PTC手中更值钱 PTC愿意支付1.11亿美元首付款，不只是看中ST-920的临床和监管进展，更因为这项资产与其现有业务高度契合。PTC长期深耕罕见病，并已有基因疗法商业化经验。2024年，其AADC缺乏症基因疗法Kebilidi获得FDA批准；公司已经具备罕见病所需的医学、患者服务和商业化基础设施，团队中也有Fabry病市场经验。CEO Matthew Klein因此表示，ST-920可以直接嵌入现有体系，无需大规模新建能力，这也是PTC眼中的“special opportunity”。这背后是并购中一个很重要的逻辑：同一项资产，对不同买家的价值并不相同。对需要从头搭建团队和商业体系的买家而言，收购只是投入的开始；对PTC而言，ST-920可以直接进入已有平台，以较低的新增成本转化为新的增长机会。 Fabry基因治疗管线收缩，进一步放大了后期资产的稀缺性 Fabry病目前仍以酶替代疗法（ERT）为重要治疗手段。Sanofi的Fabrazyme已经在美国上市多年，其他市场还有Takeda的Replagal；Amicus的Galafold则为部分适用患者提供了口服分子伴侣治疗选择。基因治疗一度被认为可能改变Fabry病长期反复治疗的模式，也因此吸引过多家公司进入。但随着临床开发推进，这条赛道不断洗牌。Avrobio已经放弃AVR-RD-01项目，其他Fabry基因治疗项目仍处于不同的临床开发阶段。相比之下，ST-920已经进入BLA滚动提交阶段，成为距离监管终点最近的资产之一。这也进一步解释了那个看起来有些矛盾的场景：卖方已经破产，买方却越抢越贵。Sangamo没有足够的资金继续把ST-920推向市场，不代表这款药本身失去了价值；相反，当一个资产已经完成了最昂贵、风险最高的一大段开发旅程，剩下的路又恰好可以由新的买家接着走，它的稀缺性反而会变得更加明显。 公司倒下，资产未必归零 Sangamo从基因编辑先驱走到破产保护，是一家Biotech的失败；但ST-920从2500万美元的初始报价一路竞价到1.11亿美元首付款，又说明公司的命运与单个资产的价值并不总是同步。公司可以因为资金、战略或执行问题走到尽头，真正有价值的资产却可能在新的主人手里继续走下去。这或许才是这场拍卖最值得记住的地方：Sangamo倒下了，但它创造的价值并没有随之消失。 PTC Therapeutics 成立于1998年的美国生物制药公司，长期聚焦罕见病药物的发现、开发与商业化，已建立从研发到全球商业化的完整能力，并拥有多款罕见病获批产品。2024年，其AADC缺乏症基因疗法Kebilidi获FDA批准，使公司进一步积累了基因疗法商业化经验。本次Sangamo破产拍卖中，PTC以1.11亿美元首付 + 最高1亿美元里程碑款赢得Fabry病基因疗法ST-920.   https://www.ptcbio.com/ Sangamo Therapeutics 成立于1995年的美国基因组医学公司，是锌指蛋白（ZFP/ZFN）技术领域的早期开拓者之一，长期开发基因编辑、基因调控和AAV递送技术，并曾开展早期人体内基因编辑临床研究。2026年6月23日，公司申请Chapter 11破产保护，随后通过法院监督的拍卖程序出售包括ST-920、锌指技术平台和AAV衣壳平台在内的核心资产。 https://www.sangamo.com/ Astellas Pharma 日本大型跨国制药企业，产品覆盖肿瘤、眼科、泌尿、免疫和女性健康等领域，同时布局基因治疗等新型治疗技术。2026年6月，Astellas成为Sangamo Fabry病基因疗法ST-920的基准竞标方，为后续法院监督的公开拍卖设定初始交易基准，但最终在竞价中败给PTC Therapeutics。 https://www.astellas.com/en 往期推荐 Nature重磅综述｜下一代ADC，真正的突破口在哪里？ 200多例死亡、15.8万不良反应：减重针还能打吗？ 33岁从零学医，40岁博士毕业：我的八年医学之路 强生7.85亿美元押注体内CAR-T：为什么Big Pharma都在抢这个赛道？ 百健（Biogen）为何突然停止"买买买"？ 差点被清算，如今22亿美元卖身：一家Biotech的绝地翻身 Science调查之后：一个基因编辑研究者的思考 Nature重磅综述：mRNA正在进入2.0时代 百济神州再投3亿美元美国建厂：一场比扩产更重要的“身份重塑” 默沙东停产，中国供货，一家美国创业公司的新玩法 【大国医药×时时】第9期：Bio归来 | 写意直播351期 细胞治疗赛道全景：谁在赚钱，谁在烧钱，谁在赌未来？ 花了3000美元参加BIO 2026，我后悔吗？ AI制药20年：烧掉数百亿美元之后，谁真正赚到了钱？ 渤健最高10亿美元收购RayThera：同一支团队三次创业、三次退出 永远在黎明前：溶瘤病毒七十年沉浮与下一次机会 ADC的进化：从重磅炸弹到技术平台 RDC赛道全景解析：ADC之后，放射性药物正在重写肿瘤治疗 DAC赛道全景解析：当精准递送遇上蛋白降解 AOC赛道全景深度解析：ADC之后，下一个百亿美元治疗模态是谁？ 资本为何重新押注RNA？从RNA Editing到RNA Therapeutics的下一轮竞赛 美国开始审查License Deal：中国创新药出海迎来最大变数？

Five years after receiving the experimental Fabry disease gene therapy AVR-RD-01, kidney function in all five participants remains relatively stable, according to the final results of the Canadian FACTs study, which tested the treatment candidate in men with the condition.All five patients had significant and sustained increases in blood alpha-Gal A activity, an enzyme deficient in people with Fabry. At the same time, four of the patients showed a marked drop in blood lyso-Gb3, a biomarker that reflects alpha-Gal A activity.The team of North American researchers noted that alpha-gal A activity “was observed at day 6-8 in each patient following infusion [of the gene therapy] and has remained durable for 5+ years,” with “all 5 patients … eligible to come off biweekly enzyme therapy.” Three of the men did stop enzyme treatment, the researchers noted.With these results, “we demonstrate that this therapeutic approach has merit, is durable, and should be explored in a larger clinical trial,” the team wrote.The study, “Lentivirus-mediated gene therapy for Fabry disease: 5-year End-of-Study results from the Canadian FACTs trial,” was published in the journal Clinical and Translational Medicine.In Fabry disease, mutations in the GLA gene result in a lack of functional alpha-galactosidase, or alpha-Gal A, an enzyme needed to break down the fatty compound globotriaosylceramide, known as Gb3. This enzymatic defect leads to the accumulation of Gb3 in the blood and cells, causing damage to various tissues and organs, especially the kidneys and heart.AVR-RD-01 is a one-time gene therapy designed to deliver a working copy of the GLA gene to a patient’s hematopoietic stem cells, or HSCs, which give rise to different types of blood cells. Treatment involves harvesting HSCs from a patient and exposing them to the viral vector used to carry the functional GLA gene. After a procedure to eliminate existing bone marrow cells, the modified stem cells are returned to the same patient via a transplant.Canadian FACTs was a five-year Phase 1 trial (NCT02800070) that tested the gene therapy in five men, ages 29-48, with classic Fabry. All of the participants had been previously treated with enzyme replacement therapy (ERT), used to manage Fabry.Interim results reported in 2021 showed that alpha-Gal A rose to near-normal levels within a week of receiving AVR-RD-01. Although enzyme activity decreased over time, almost three years later, such activity remained above levels typically found in Fabry patients. In 2024, a follow-up analysis showed sustained reductions in Gb3 and lyso-Gb3 in treated patients.Meanwhile, the FAB-GT Phase 1/2 open-label trial (NCT03454893) was launched to evaluate AVR-RD-01 in males with Fabry, ages 16-50, who had not received previous treatment. However, some patients showed unexpected drops in alpha-Gal A activity and signs that the modified stem cells were not growing in the bone marrow as expected.Given these findings, Avrobio, the developer of AVR-RD-01, deprioritized its Fabry program in early 2022, and enrollment in the FAB-GT trial was stopped.In this report, Canadian FACTs investigators presented the final results of the study, focusing on years one through five, as earlier time points already were reported.The data showed that blood levels of alpha-Gal A significantly increased in all five patients up to five years after their stem cell transplant. Still, those levels remained below the normal range in all patients except for one, who had sustained normal levels. Enzyme activity levels in white blood cells followed a similar pattern.Throughout the study, blood Gb3 levels dropped in all patients, remaining in the normal range at year five. While all participants were eligible to do so, three chose to stop ERT during the trial.The researchers noted that pausing ERT in those three participants had saved the Canadian public health care system about $5 million at the time of the last patient visit. Moreover, ERT cost savings continue to increase as all five patients are involved in a 15-year follow-up.Blood lyso-Gb3, a recognized metabolite of interest in Fabry that correlates with disease outcomes, significantly decreased in four patients. Half had stopped ERT, and half had continued. The fifth patient, who had also stopped ERT, had a small but significant increase in lyso-Gb3.Kidney function remained relatively stable for up to five years in all patients, as measured by the estimated glomerular filtration rate (eGFR), which measures how well the kidneys work.Three patients’ kidney function slightly decreased throughout the study, but their eGFR values remained normal. One patient with mild kidney disease at the time of transplant maintained kidney function without eGFR decline, while another who started with moderate kidney disease experienced a more rapid and variable decline.All patients showed slightly increasing levels of troponin, a biomarker of heart muscle inflammation. Three patients, two of whom remained on ERT, had a short-term increase in the left ventricular mass index, a measure of the heart’s left ventricle mass, which resolved at five years. No signs of heart fibrosis, or scarring, were seen in any evaluable patient, and all blood pressures were in the normal range.Although antibodies against alpha-Gal A increased in three patients after the transplant, all remained at or near pretreatment levels beyond 18 months, or 1.5 years.Two adverse events occurring during the treatment phase were previously reported: One patient experienced fever with a low white blood cell count, known as febrile neutropenia, and another had a catheter-related infection. Since then, one patient experienced a moderate incident of vomiting and another of wheezing/asthma.“Treating patients with [HSCs] engineered to express [alpha-Gal A] continues to be a safe therapy for Fabry disease patients,” the researchers wrote.The team noted that FACTs was designed as a safety study.“Future clinical trials in this area would aim to expand the patient cohort examined in this study as well as include female Fabry disease patients and younger male [patients],” the team wrote, adding that “the fact that all five treated patients responded positively to the gene therapy bodes well for outcomes in a larger study.”